Novel administration routes for allergen-specific immunotherapy: a review of intralymphatic and epicutaneous allergen-specific immunotherapy
S von Moos, TM Kündig, G Senti - … and Allergy Clinics, 2011 - immunology.theclinics.com
The prevalence of allergic diseases, first described by John Bostock at the beginning of the
19th century as catarrhus aestivus, 1 has been continually increasing and has actually
reached epidemic dimensions. 2 Initially conceived as a toxin-induced disease, 3 the
pathophysiologic understanding of allergy fundamentally changed in 1986 with the
discovery of immunoglobulin E (IgE). 4 However, despite such paradigm change with regard
to the causative factor of allergy, treatment options have remained
19th century as catarrhus aestivus, 1 has been continually increasing and has actually
reached epidemic dimensions. 2 Initially conceived as a toxin-induced disease, 3 the
pathophysiologic understanding of allergy fundamentally changed in 1986 with the
discovery of immunoglobulin E (IgE). 4 However, despite such paradigm change with regard
to the causative factor of allergy, treatment options have remained